Ramoplanin: Phase II; Phase III for vancomycin-resistant enterococci

GENE began an open-label U.S. Phase II trial of 200 mg or 400 mg of twice-daily Ramoplanin compared to vancomycin in 87 patients. Patients will be treated for 10 days. GENE received exclusive North Am...